Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valneva SEVALN +0.67%49 3-Year EPS without NRI Growth Rate is 14.40% as of Jun. 2026. GuruFocus rates VALN with a GF Score™ of 49/100 and a GF Value™ of $5.32 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,160 Biotechnology companies, Valneva SE ranks worse than 52.59% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 14.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 20.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Valneva SE was 95.20% per year. The lowest was -251.80% per year. And the median was -0.75% per year.
Valneva SE (NAS:VALN) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Valneva SE 3-Year EPS without NRI Growth Rate Related Terms
VALN vs VRTX, REGN, MRNA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Valneva SE's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Valneva SE's 3-Year EPS without NRI Growth Rate falls into.
Valneva SE 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 14.40% mean?
Valneva SE (VALN) has a 3-Year EPS without NRI Growth Rate of 14.40% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Valneva SE and its competitors. According to the industry distribution chart, Valneva SE ranks #610 out of 1160 companies in the Biotechnology industry, placing it in the top 52.6%.
Is Valneva SE's 3-Year EPS without NRI Growth Rate too high?
Valneva SE's current 3-Year EPS without NRI Growth Rate is 14.40%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.95. Valneva SE's value of 14.40% is 9.7% below this industry median. Based on the distribution chart, Valneva SE ranks #610 out of 1160 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Valneva SE has a GF Score™ of 49/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #610 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Valneva SE in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.95. Valneva SE's value of 14.40% is 9.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valneva SE's current 3-Year EPS without NRI Growth Rate of 14.40% is 9.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Valneva SE and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current 3-Year EPS without NRI Growth Rate is 14.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (VALN) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.73 — trading 26.4% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 14.40% and 9.7% below the Biotechnology industry median of 15.95. Valneva SE's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Valneva SE (VALN), the current 3-Year EPS without NRI Growth Rate is 14.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (VALN) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be overvalued.
The current stock price of $6.73 is trading 26.4% above its estimated GF Value™ of $5.32.
GuruFocus considers Valneva SE to be Modestly Overvalued.
Key valuation signals for VALN:
3-Year EPS without NRI Growth Rate: 14.40%
GF Value™: $5.32 vs. price of $6.73 (26.4% above fair value)
Industry Position: 9.7% below the Biotechnology median (#610 of 1160)
No single metric tells the full story. See the VALN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
49GF Score
Get the complete analysis for VALN
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VALN has been successfully added to your 
